Piperacillin-tazobactam in pediatric cancer patients younger than 25 months : a retrospective multicenter survey

Piperacillin-Tazobactam (Pip-Taz) is an evidence-based empirical treatment of febrile neutropenia in adolescents and adults. No data are available in pediatric cancer patients

Saved in:
Bibliographic Details
Published in:European journal of clinical microbiology & infectious diseases 2007-11, Vol.26 (11), p.801-806
Main Authors: SIMON, A, LEHRNBECHER, T, BODE, U, GROLL, A. H, TRAMSEN, L, WIELAND, R, MOLITOR, E, FLEISCHHACK, G, LAWS, H. J
Format: Article
Language:English
Subjects:
Adolescents
Age
Allergic reactions
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - drug therapy
Biological and medical sciences
Cancer
Cancer therapies
Children
Chronic obstructive pulmonary disease, asthma
Empirical analysis
Fever
Fever of Unknown Origin - drug therapy
Hematologic and hematopoietic diseases
Humans
Hypersensitivity
Infant
Infant, Newborn
Medical research
Medical sciences
Neoplasms - complications
Neutropenia
Other diseases. Hematologic involvement in other diseases
Patients
Pediatrics
Penicillanic Acid - administration & dosage
Penicillanic Acid - adverse effects
Penicillanic Acid - analogs & derivatives
Penicillanic Acid - therapeutic use
Pharmacology. Drug treatments
Piperacillin
Piperacillin - administration & dosage
Piperacillin - adverse effects
Piperacillin - therapeutic use
Piperacillin-tazobactam
Pneumology
Retrospective Studies
Surveys
Tazobactam
Treatment Outcome
Wheezing
Withholding Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Piperacillin-Tazobactam (Pip-Taz) is an evidence-based empirical treatment of febrile neutropenia in adolescents and adults. No data are available in pediatric cancer patients
ISSN:0934-9723
1435-4373
DOI:10.1007/s10096-007-0382-5